PUBLICATIONS AND PresentationS
Discover the main highlights of our industry in our latest publications.
Quick links
Presentation
Publication
Key Economic & Value Considerations in the US
Market for PPTs
Market for PPTs
Key Economic & Value Considerations for PDMPs
in Europe
in Europe
Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Apr 9, 2025
Who are US Source Plasma donors? Results from a preliminary analysis
All
Publication
Apr 9, 2025
Who are US Source Plasma donors? Results from a preliminary analysis
All
Publication
Dec 1, 2024
Adverse Events Among U.S. Source Plasma Donors – Plasmavigilance II
As a follow up to the 2021 PPTA study, “Plasmavigilance – Adverse Events Among U.S. Source Plasma [SP] Donors,” published in Transfusion, PPTA analyzed hypotensive adverse events (HAE) rates and SP donor characteristics that may be predictors of a HAE.
All
Publication
https://drive.google.com/file/d/1gAF8US04_IE6h0a3-ERhGlWTV91xGa82/view
Dec 1, 2024
Adverse Events Among U.S. Source Plasma Donors – Plasmavigilance II
As a follow up to the 2021 PPTA study, “Plasmavigilance – Adverse Events Among U.S. Source Plasma [SP] Donors,” published in Transfusion, PPTA analyzed hypotensive adverse events (HAE) rates and SP donor characteristics that may be predictors of a HAE.
All
Publication
https://drive.google.com/file/d/1gAF8US04_IE6h0a3-ERhGlWTV91xGa82/view
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Sep 1, 2021
Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
In the coming decade European countries will see an increased need for plasma-derived medicines to treat their patients for a range of rare diseases and critical medical conditions. While demand for blood components for transfusion remains relatively stable, a European Commission survey (2014) shows that demand for plasma derivatives is increasing by some 6% per year.
All
Publication
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64524317f82dbf9d9297bca9_Plasma_core_policy_report_2022web.pdf
Sep 1, 2021
Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
In the coming decade European countries will see an increased need for plasma-derived medicines to treat their patients for a range of rare diseases and critical medical conditions. While demand for blood components for transfusion remains relatively stable, a European Commission survey (2014) shows that demand for plasma derivatives is increasing by some 6% per year.
All
Publication
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64524317f82dbf9d9297bca9_Plasma_core_policy_report_2022web.pdf
No results found